Preliminary study on xenotransfusion from porcine red blood cell into Rhesus monkey.
- Author:
Ying-Xia TAN
1
;
Shou-Ping JI
;
Yan-Ping LU
;
Cheng-Lin ZHANG
;
Li-Li LI
;
Feng GONG
;
Jin-Guo ZHANG
;
Yang-Pei ZHANG
Author Information
1. Institute of Transfusion Medicine, Academy of Military Medical Sciences, Beijing 100850, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Erythrocyte Transfusion;
methods;
Erythrocytes;
drug effects;
immunology;
Hemagglutination Tests;
Macaca mulatta;
immunology;
Polyethylene Glycols;
pharmacology;
Swine;
blood;
Transplantation, Heterologous;
methods;
alpha-Galactosidase;
pharmacology
- From:
Journal of Experimental Hematology
2006;14(1):150-155
- CountryChina
- Language:Chinese
-
Abstract:
In order to study the possibility of xenotransfusion from porcine red blood cell (pRBC) to primate, the antigens on pRBC surface were modified to make it more compatible to primate sera. Porcine RBCs were subjected to both enzymatic removal of membrane alpha-Gal antigens with recombinant alpha-galactosidase (AGL) and covalent attachment of succinimid propionate-linked methoxypolyethyleneglycol (mPEG-SPA) to camouflage non-alphaGal antigens. The effects of double modifications were determinated by hemagglutination and clinical cross-match testing with rhesus sera. In vivo clearance rates and safety of modified pRBCs were measured after it was transfused into Rhesus monkey with or without immunosuppressant treatment. The validity of pRBC was detected in exsanguine Rhesus monkey model. The results showed that AGL could effectively remove alpha-Gal xenoantigens on pRBC membrane and reduce hemagglutination. The combination of mPEG modification with AGL treatment could significantly increased compatibility between pRBCs and Rhesus monkey sera. Modified pRBCs were detectable in Rhesus monkey blood at 12 hours after transfusion, and their survival time was 40 hours in the immunosuppressant-treated Rhesus monkey. In vivo survival rates of pRBCs were 38% in exsanguine Rhesus monkey at 8 hours after transfusion, and during that time, the hemoglobin and hematocrit of Rhesus monkey were maintained at the same level as before it lost blood. It is concluded that the modified pRBC can be safely transfused into Rhesus monkey and relieve the anemic symptom exsanguine Rhesus monkey. It suggested that pRBC can be hopefully used as a blood substitute for primate and human in the future.
